Browsing by Author "Prockop, Darwin J."

Now showing 1 - 17 of 17
  • Thumbnail Image
    Item
    Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
    (United States. Patent and Trademark Office, 2015-06-23) Prockop, Darwin J.; Oh, Joo Youn; Berkowitz, Barry; Roddy, Gavin W.; Rosa, Robert; Temple Therapeutics, Inc.; Scott & White Healthcare
    The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
  • Thumbnail Image
    Item
    Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
    (United States. Patent and Trademark Office, 2017-08-15) Prockop, Darwin J.; Oh, Joo Youn; Berkowitz, Barry; Roddy, Gavin W.; Rosa, Robert; The Texas A&M University System; Temple Therapeutics, Inc.; Scott & White Healthcare
    The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
  • Thumbnail Image
    Item
    Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
    (United States. Patent and Trademark Office, 2018-10-23) Prockop, Darwin J.; Oh, Joo Youn; Berkowitz, Barry; Roddy, Gavin W.; Rosa, Robert; The Texas A&M University System; Temple Therapeutics, Inc.
    The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
  • Thumbnail Image
    Item
    Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
    (United States. Patent and Trademark Office, 2014-07-22) Prockop, Darwin J.; Oh, Joo Youn; Roddy, Gavin W.; Rosa, Robert; Berkowitz, Barry A.; The Texas A & M University System; Temple Therapeutics, Inc.
    The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
  • Thumbnail Image
    Item
    Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases
    (United States. Patent and Trademark Office, 2017-01-17) Prockop, Darwin J.; Oh, Joo Youn; Berkowitz, Barry; The Texas A&M University System; Temple Therapeutics, Inc.
    The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.
  • Thumbnail Image
    Item
    Compositions of mesenchymal stem cells to regenerate bone
    (United States. Patent and Trademark Office, 2016-12-06) Gregory, Carl A.; Prockop, Darwin J.; The Texas A & M University System
    The present invention encompasses an osteogenic composition comprising mesenchymal stem cells pre-cultured in the presence of an agent that accelerates canonical Wnt signaling therein. Also, provided are osteogenic compositions incorporated into a biocompatible gel. The present invention provides methods for treating bone degeneration or injury associated with a pathophysiological condition in a mammal or for accelerating repair of a skeletal injury in a mammal by administering to the mammal or contacting the site of injury with the osteogenic composition.
  • Thumbnail Image
    Item
    In Vitro Properties of Human Mesenchymal Stem Cells and Their Ability to Modulate Inflammation in Vivo
    (2015-05-01) Bazhanov, Nikolay; Prockop, Darwin J.; Sullivan, Deborah E.; Gregory, Carl A.; Gashev, Anatoliy A.
    Mesenchymal stem cells (MSCs), are plastic adherent cells that are readily isolated from various sources, possess stem-cell-like properties and show unique beneficial features in in vivo models of diseases. In present dissertation we investigated the aspects of MSCs biology related to both in vitro properties and in vivo abilities to benefit in diseases. The in vitro part of the dissertation addresses the question of heterogeneity in single-cell derived cultures of human MSCs. Laser capture microdissection was used to isolate distinct inside and outside regions of the colony for RNA isolation. When assayed by microarray the cells from inside and outside regions of the colony showed distinct patterns of gene expression profile. In functional studies, however, we did not find any differences – the cells perform similarly in cloning and in vitro growth assays. In the in vivo part of the dissertation we investigated the effects of human MSCs and their secreted protein tumor-necrosis factor stimulated gene/protein 6 (TSG-6) in two models of lung injury - hydrocloric-acid (HCl)-induced lung injury and bleomycininduced lung injury in mice. We showed that intraperitoneal administration (IP) of human MSCs improved lung function and inhibited inflammation in the lungs after HCl lung injury. Human recombinant TSG-6 inhibited inflammation in both, HCl-induced lung injury and bleomycin-induced lung injury, however it improved lung function only in mice injured with bleomycin. Finally we investigated the effects of MSCs administered inside the peritoneal cavity to explain the beneficial effects in HCl-induced lung injury. We showed that MSCs aggregated rapidly after the injection IP and preconditioned immune system by recruiting immune cells to peritoneal cavity and by triggering the production of various classes of cytokines. We utilized real-time polymerase chain reaction (PCR) and in vivo imaging to estimate the amount MSCs present in various organs of peritoneal cavity. Most of MSCs were found in omentum and mesenteric tissues, only negligible amount of cells was recovered from lymph nodes and spleen. In conclusion, the dissertation is expanding the existing knowledge about MSCs, increases our knowledge both in understanding the basic biology of the cells and their interaction with the host organism.
  • Thumbnail Image
    Item
    Mesenchymal stem cells derived from induced pluripotent stem cells
    (United States. Patent and Trademark Office, 2019-07-16) Prockop, Darwin J.; Lui, Fei; Zhao, Qingguo; Berkowitz, Barry A.; THE TEXAS A&M UNIVERSITY SYSTEM; TEMPLE THERAPEUTICS, INC.
    "A method of producing mesenchymal stem cells from induced pluripotent stem cells in which induced pluripotent stem cells are cultured in the presence of a TGF-β inhibitor an in an atmosphere containing from about 7 vol. % to about 8 vol. % CO2 for a period of time from about 20 day to about 35 days. The cells then are transferred to a culture dish having a hydrophilic surface, and the cells are cultured in a medium containing a TGF-β inhibitor for a period of time sufficient to produce mesenchymal stem cells. Such mesenchymal stem cells are more stable and less likely to form tumors, cancers, or teratomas. Also, the induced pluripotent stem cells may be genetically engineered with at least one polynucleotide encoding a therapeutic agent and then are cultured as hereinabove described to provide genetically engineered mesenchymal stem cells that express sustained amounts of a biologically active protein or polypeptide.
  • Thumbnail Image
    Item
    Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
    (United States. Patent and Trademark Office, 2018-07-31) Prockop, Darwin J.; Lee, Ryanghwa; The Texas A&M University System
    The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and inflammatory disease. The compositions of the invention may be particularly useful in restoring cardiac function following cardiac damage, including, but not limited to, myocardial infarction, as well as in reducing symptoms of inflammatory disease.
  • Thumbnail Image
    Item
    Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
    (United States. Patent and Trademark Office, 2014-06-24) Rosa, Robert; Roddy, Gavin W.; Prockop, Darwin J.; Scott & White Healthcare; The Texas A&M University System
    The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
  • Thumbnail Image
    Item
    Protein therapy for treatment of retinal diseases
    (United States. Patent and Trademark Office, 2015-07-28) Rosa, Robert; Roddy, Gavin W.; Prockop, Darwin J.; Scott & White Healthcare; The Texas A&M University System
    The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
  • Thumbnail Image
    Item
    Rapidly Self-Renewing Human Multipotent Marrow Stromal Cells (hMSC) Express Sialyl Lewis X and Actively Adhere to Arterial Endothelium in a Chick Embryo Model System
    (PloS One, 2014) McFerrin, Harris E.; Olson, Scott D.; Gutschow, Miriam V.; Semon, Julie A.; Sullivan, Deborah E.; Prockop, Darwin J.; Engler, Adam J.
  • Thumbnail Image
    Item
    Scalable Production of a Multifunctional Protein (TSG-6) That Aggregates with Itself and the CHO Cells That Synthesize It
    (PloS One, 2016) Kim, Dong-Ki; Choi, Hosoon; Nishida, Hidetaka; Oh, Joo Youn; Gregory, Carl; Lee, Ryang Hwa; Yu, Ji Min; Watanabe, Jun; An, Su Yeon; Bartosh, Thomas J.; Prockop, Darwin J.; Kerkis, Irina
  • Thumbnail Image
    Item
    Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof
    (United States. Patent and Trademark Office, 2021-11-02T00:00:00Z) Prockop, Darwin J.; Kim, Dong-Ki; Nishida, Hidetaka; Shetty, Askok K.; Texas A&M University System
    Preparations comprising an enriched population of extracellular vesicles (nEVs) having a negatively charged surface, and that are CD81+ and CD9-, are provided. Improved processes and methods for producing an enriched population of nEVs from non-murine cells, especially human origin cells and/or tissues, are disclosed. Therapeutic methods for using the preparations, including for reducing brain inflammation and treatment of various pathologies associated with brain inflammation, such as by intravenous or intranasal administration, are also described. Methods and preparations for reducing brain inflammation associated with traumatic brain injury (TBI) are also disclosed. A method for treating a patient having suffered a mild traumatic injury (mTMI), or concussion, such as a sports-related head injury, is also disclosed. The nEVs are also demonstrated to reduce the expression level of IL-I.beta. in brain tissue of an animal having had traumatic brain injury. Methods for improving cognitive function and performance in animals after a traumatic brain injury is also demonstrated using the preparations of nEVs disclosed herein.
  • Thumbnail Image
    Item
    Stanniocalcin-1 (STC-1) therapy for treatment of retinal diseases
    (United States. Patent and Trademark Office, 2016-11-22) Rosa, Robert; Roddy, Gavin W.; Prockop, Darwin J.; Scott & White Healthcare; The Texas A&M University System
    The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein.
  • Thumbnail Image
    Item
    Stanniocalcin-1 Regulates Extracellular ATP-Induced Calcium Waves in Human Epithelial Cancer Cells by Stimulating ATP Release from Bystander Cells
    (PloS One, 2010) Block, Gregory J.; DiMattia, Gabriel D.; Prockop, Darwin J.; Hotchin, Neil A.
  • Thumbnail Image
    Item
    Treatment of gum diseases and gum disorders with TSG-6 protein
    (United States. Patent and Trademark Office, 2017-06-13) Prockop, Darwin J.; Svoboda, Kathy K. H.; Beltran, Stacy Renay; The Texas A & M University System
    A method of treating or preventing a gum disease or gum disorder or gum injury in a mammal by administering to the mammal at least one inflammation modulatory or anti-inflammatory protein or polypeptide, such as TSG-6 protein, or a biologically active fragment, derivative, or analogue thereof. Gum diseases or gum disorders or gum injuries that may be treated include periodontal gum disease, and gum wounds resulting from gum surgeries.